At the news
? NEUTRALIMPACT 3/10 PRESS-RELEASE filed Jun 15, 2026 at 07:00 ET
Axsome Therapeutics presented new data on AXS-12 and solriamfetol at SLEEP 2026, including cognitive/functional outcomes from the Phase 3 ENCORE trial and post-hoc composite endpoint analyses. The presentations do not contain new regulatory milestones, financial results, or concrete catalysts, this is a routine scientific conference update without material new information for the stock.
- Presented Phase 3 ENCORE trial data for AXS-12 in narcolepsy with cataplexy at SLEEP 2026
- Presented post-hoc composite endpoint analysis of solriamfetol Phase 3 trials in narcolepsy and OSA
- Presented subgroup analysis from CRESCENDO survey on residual cataplexy symptom burden
- No new approvals, regulatory submissions, or financial guidance were announced
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access